Haematology 2018

Investigator-assessed PFS (primary endpoint)

Kaplan-Meier plot of investigator-assessed PFS by treatment arm

R-CHOP, n=712

G-CHOP, n=706

1.0

215 (30.2)

201 (28.5)

Pts with event, n (%)

0.8

1-yr PFS, %

79.8

81.6

0.6

2-yr PFS, %

71.3

73.4

0.4

Probability

0.2

3-yr PFS, %

66.9

69.6

R-CHOP (n=712) G-CHOP (n=706)

HR (95% CI), p-value*

0.92 (0.76, 1.11), p=0.3868

0

0

6 12 18 24 30 36 42 48 54 Time (months)

60

No. of patients at risk R-CHOP G-CHOP 712 706

Median follow-up: 29 months

616 622

527 540

488 502

413 425

227 240

142 158

96 102

41 39

6 2

*Stratified analysis; stratification factors: IPI score, number of planned chemotherapy cycles

Vitolo et al ASH 2016 and J Clin Oncol. 2017 Nov 1;35(31):3529-3537

41